Company did not provide specific guidance for the current quarter or full year
Overview
US translational oncology research firm's fiscal Q1 revenue grew 8.8% yr/yr
Oncology services margin improved to 51% from 43% in prior-year period
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$15.23 mln
Q1 Adjusted EPS
$0.05
Result drivers
Research services execution - Co said improved study execution and conversion in core research services business drove higher revenue and better margins
Data license revenue - Increased commercial activity around data offerings contributed to revenue growth
Lower radiolabeling costs - Oncology services margin improved due to higher revenue and lower third-party radiolabeling costs
CSBR•
